Synergy between anions and farnesyldiphosphate competitive inhibitors of farnesyl:protein transferase.
Investigation of the comparative activities of various inhibitors of farnesyl:protein transferase (FPTase) has led to the observation that the presence of phosphate or pyrophosphate ions in the assay buffer increases the potency of farnesyl diphosphate (FPP) competitive inhibitors. In addition to exploring the phenomenon of phosphate synergy, we report here the effects of various other ions including sulfate, bicarbonate, and chloride on the inhibitory ability of three FPP competitive compounds: Cbz-His-Tyr-Ser(OBn)TrpNH2 (2), Cbz-HisTyr(OPO42-)-Ser(OBn)TrpNH2 (3), and alpha-hydroxyfarnesyl phosphonic acid (4). Detailed kinetic analysis of FPTase inhibition revealed a high degree of synergy for compound 2 and each of these ions. Phosphorylation of 2 to give 3 completely eliminated any ionic synergistic effect. Moreover, these ions have an antagonistic effect on the inhibitory potency of compound 4. The anions in the absence of inhibitor exhibit non-competitive inhibition with respect to FPP. These results suggest that phosphate, pyrophosphate, bicarbonate, sulfate, and chloride ions may be binding at the active site of both free enzyme and product-bound enzyme with normal substrates. These bound complexes increase the potency of FPP competitive inhibitors and mimic an enzyme:product form of the enzyme. None of the anions studied here proved to be synergistic with respect to inhibition of geranylgeranyl transferase I. These findings provide insight into the mechanism of action of FPP competitive inhibitors for FPTase and point to enzymatic differences between FPTase and geranylgeranyl transferase I that may facilitate the design of more potent and specific inhibitors for these therapeutically relevant target enzymes.
Scholten
J D
JD
Department of Biochemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA. scholtj@aa.wl.com
Zimmerman
K K
KK
Oxender
M G
MG
Leonard
D
D
Sebolt-Leopold
J
J
Gowan
R
R
Hupe
D J
DJ
D019883:Alkyl and Aryl Transferases; D000818:Animals; D000838:Anions / Q000494:pharmacology; D001667:Binding, Competitive; D002460:Cell Line; D004357:Drug Synergism; D007700:Kinetics; D008956:Models, Chemical; D009842:Oligopeptides / Q000494:pharmacology; D011106:Polyisoprenyl Phosphates / Q000494:pharmacology*; D017368:Protein Prenylation; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000302:isolation & purification; D012717:Sesquiterpenes; D018411:Spodoptera; D014162:Transfection; D014166:Transferases / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000302:isolation & purification / Q000378:metabolism
D000838:Anions; D009842:Oligopeptides; D011106:Polyisoprenyl Phosphates; D011994:Recombinant Proteins; D012717:Sesquiterpenes; C004808:farnesyl pyrophosphate; D014166:Transferases; D019883:Alkyl and Aryl Transferases; C083291:geranylgeranyltransferase type-I; C064911:p21(ras) farnesyl-protein transferase